Journal article
Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature
Melanoma research, Vol.31(1), pp.98-100
02/01/2021
DOI: 10.1097/CMR.0000000000000713
PMID: 33323722
Abstract
Pembrolizumab is a humanized IgG4 isotype mAb that the targets and blocks the programmed cell death protein 1 receptor on lymphocytes. Its use in treating metastatic melanoma is associated with increased overall survival compared to other older immunotherapies. Several adverse effects have been noted including both systemic and cutaneous manifestations. As a relatively novel treatment option, many new cutaneous manifestations are still being observed, occurring at various times after initiation of therapy. Previously noted cutaneous adverse effects include sarcoid-like reactions, rash, and changes in preexisting lesions or scars. Here we present a case in which biopsy-proven morphea developed after completion of pembrolizumab therapy.
Details
- Title: Subtitle
- Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature
- Creators
- Faraaz S. Zafar - University of IowaPatricia Richey - University of IowaUchenna Okereke - University of Iowa Hospitals and ClinicsMohammed Milhem - University of Iowa Hospitals and ClinicsRoshan Abid - University of IowaJennifer G. Powers - University of Iowa Hospitals and Clinics
- Resource Type
- Journal article
- Publication Details
- Melanoma research, Vol.31(1), pp.98-100
- Publisher
- Lippincott Williams & Wilkins
- DOI
- 10.1097/CMR.0000000000000713
- PMID
- 33323722
- ISSN
- 0960-8931
- eISSN
- 1473-5636
- Number of pages
- 3
- Language
- English
- Date published
- 02/01/2021
- Academic Unit
- Dermatology; Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984360057002771
Metrics
9 Record Views